The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.
dc.contributor.author | Na, Il-Kang | |
dc.contributor.author | Lu, Sydney X | |
dc.contributor.author | Yim, Nury L | |
dc.contributor.author | Goldberg, Gabrielle L | |
dc.contributor.author | Tsai, Jennifer | |
dc.contributor.author | Rao, Uttam | |
dc.contributor.author | Smith, Odette M | |
dc.contributor.author | King, Christopher G | |
dc.contributor.author | Suh, David | |
dc.contributor.author | Hirschhorn-Cymerman, Daniel | |
dc.contributor.author | Palomba, Lia | |
dc.contributor.author | Penack, Olaf | |
dc.contributor.author | Holland, Amanda M | |
dc.contributor.author | Jenq, Robert R | |
dc.contributor.author | Ghosh, Arnab | |
dc.contributor.author | Tran, Hien | |
dc.contributor.author | Merghoub, Taha | |
dc.contributor.author | Liu, Chen | |
dc.contributor.author | Sempowski, Gregory D | |
dc.contributor.author | Ventevogel, Melissa | |
dc.contributor.author | Beauchemin, Nicole | |
dc.contributor.author | van den Brink, Marcel RM | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2011-06-21T17:27:54Z | |
dc.date.issued | 2010-01 | |
dc.description.abstract | Thymic graft-versus-host disease (tGVHD) can contribute to profound T cell deficiency and repertoire restriction after allogeneic BM transplantation (allo-BMT). However, the cellular mechanisms of tGVHD and interactions between donor alloreactive T cells and thymic tissues remain poorly defined. Using clinically relevant murine allo-BMT models, we show here that even minimal numbers of donor alloreactive T cells, which caused mild nonlethal systemic graft-versus-host disease, were sufficient to damage the thymus, delay T lineage reconstitution, and compromise donor peripheral T cell function. Furthermore, to mediate tGVHD, donor alloreactive T cells required trafficking molecules, including CCR9, L selectin, P selectin glycoprotein ligand-1, the integrin subunits alphaE and beta7, CCR2, and CXCR3, and costimulatory/inhibitory molecules, including Ox40 and carcinoembryonic antigen-associated cell adhesion molecule 1. We found that radiation in BMT conditioning regimens upregulated expression of the death receptors Fas and death receptor 5 (DR5) on thymic stromal cells (especially epithelium), while decreasing expression of the antiapoptotic regulator cellular caspase-8-like inhibitory protein. Donor alloreactive T cells used the cognate proteins FasL and TNF-related apoptosis-inducing ligand (TRAIL) (but not TNF or perforin) to mediate tGVHD, thereby damaging thymic stromal cells, cytoarchitecture, and function. Strategies that interfere with Fas/FasL and TRAIL/DR5 interactions may therefore represent a means to attenuate tGVHD and improve T cell reconstitution in allo-BMT recipients. | |
dc.description.version | Version of Record | |
dc.identifier | ||
dc.identifier | 39395 | |
dc.identifier.eissn | 1558-8238 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.language.iso | en_US | |
dc.publisher | American Society for Clinical Investigation | |
dc.relation.ispartof | J Clin Invest | |
dc.relation.isversionof | 10.1172/JCI39395 | |
dc.relation.journal | Journal of Clinical Investigation | |
dc.subject | Animals | |
dc.subject | Bone Marrow Transplantation | |
dc.subject | CASP8 and FADD-Like Apoptosis Regulating Protein | |
dc.subject | Cell Movement | |
dc.subject | Fas Ligand Protein | |
dc.subject | Graft vs Host Disease | |
dc.subject | Lymphocyte Activation | |
dc.subject | Mice | |
dc.subject | Mice, Inbred BALB C | |
dc.subject | Mice, Inbred C57BL | |
dc.subject | Receptors, OX40 | |
dc.subject | Receptors, TNF-Related Apoptosis-Inducing Ligand | |
dc.subject | Stromal Cells | |
dc.subject | T-Lymphocytes | |
dc.subject | TNF-Related Apoptosis-Inducing Ligand | |
dc.subject | Thymus Gland | |
dc.subject | Transplantation, Homologous | |
dc.title | The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. | |
dc.title.alternative | ||
dc.type | Journal article | |
duke.contributor.orcid | Sempowski, Gregory D|0000-0003-0391-6594 | |
duke.date.pubdate | 2010-1-0 | |
duke.description.issue | 1 | |
duke.description.volume | 120 | |
pubs.author-url | ||
pubs.begin-page | 343 | |
pubs.end-page | 356 | |
pubs.issue | 1 | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Duke Human Vaccine Institute | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Medicine, Duke Human Vaccine Institute | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | School of Medicine | |
pubs.publication-status | Published | |
pubs.volume | 120 |